Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The overall purpose of this project is to develop and test an infrastructure that can ensure early and specialized rehabilitation for individuals with multiple sclerosis (MS) on their path to recovery from a relapse. If this project proves successful, it can therefore help optimize clinical practice and provide a significant contribution to the treatment of relapsing-remitting sclerosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• admitted to the Danish MS Hospitals for an inpatient rehabilitation stay

• confirmed motor relapse (within the past 6 months) by a neurologist, with disability/ functional interference characterized by change in pyramidal, and/or cerebellar functional scores of 2 or higher

• completed steroid or other acute relapse treatment, if prescribed

• age over 18 years

Locations
Other Locations
Denmark
The Danish MS Hospitals
RECRUITING
Haslev
The Danish MS Hospitals
RECRUITING
Ry
Contact Information
Primary
Lars Hvid, PhD
larshv@sclerosehospital.dk
+4593508717
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 64
Treatments
Experimental: Intensive rehab
10 weeks of community-based physical therapy. Participants will receive two weekly supervised physical therapy session (45-60 minutes).~The content of this exercise program and the specific exercises and exercise methods will be planned in collaboration between MS specialists from the Danish MS hospitals, the local physical therapist, and the participant.
Active_comparator: Usual care
10 weeks of usual care physiotherapy, normally comprised of municipal rehabilitation as well as self-administered behavior.
Related Therapeutic Areas
Sponsors
Leads: Lars Hvid

This content was sourced from clinicaltrials.gov